Tscan Therapeutics is trading at $0.23, up 5.12%, with no clear company-specific catalyst identified for the October 14 move.
- The Cellares manufacturing agreement surfaced in search results but was announced in June, so it is not new news explaining the move.
- Broader markets are lower after hotter-than-expected September headline CPI, while Tscan’s gain runs counter to that pressure. No clear sector or market explanation has been established.